

# CRPL3

## C-Reactive Protein Gen.3



### Order information

REF	CONTENT	Analyzer(s) on which <b>cobas c</b> pack(s) can be used
04956842 190	C-Reactive Protein Gen.3 (250 tests)	System-ID 07 6993 2 Roche/Hitachi <b>cobas c</b> 311, <b>cobas c</b> 501/502
11355279 216	Calibrator f.a.s. Proteins (5 x 1 mL)	Code 656
11355279 160	Calibrator f.a.s. Proteins (5 x 1 mL, for USA)	Code 656
10557897 122	Precinorm Protein (3 x 1 mL)	Code 302
10557897 160	Precinorm Protein (3 x 1 mL, for USA)	Code 302
11333127 122	Precipath Protein (3 x 1 mL)	Code 303
11333127 160	Precipath Protein (3 x 1 mL, for USA)	Code 303
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

### English

#### System information

For **cobas c** 311/501 analyzers:

**CRPL3**: ACN 210

For **cobas c** 502 analyzer:

**CRPL3**: ACN 8210

#### Intended use

Immunoturbidimetric assay for the in vitro quantitative determination of CRP in human serum and plasma on Roche/Hitachi **cobas c** systems.

#### Summary<sup>1,2,3,4,5,6,7,8</sup>

C-reactive protein is the classic acute phase protein in inflammatory reactions. It is synthesized by the liver and consists of five identical polypeptide chains that form a five-membered ring having a molecular weight of 105000 daltons. CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. Complexed CRP activates the classical complement pathway. The CRP response frequently precedes clinical symptoms, including fever. In normal healthy individuals CRP is a trace protein with a range up to 5 mg/L. After onset of an acute phase response the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis). CRP response may be less pronounced in patients suffering from liver disease. CRP assays are used to detect systemic inflammatory processes; to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow rejection. Postoperative monitoring of CRP levels of patients can aid in the recognition of unexpected complications (persisting high or increasing levels). Measuring changes in the concentration of CRP provides useful diagnostic information about how acute and how serious a disease is. It also allows judgements about the disease genesis. Persistence of a high serum CRP concentration is usually a grave prognostic sign which generally indicates the presence of an uncontrolled infection.

#### Test principle<sup>9,10</sup>

Particle enhanced immunoturbidimetric assay.

Human CRP agglutinates with latex particles coated with monoclonal anti-CRP antibodies. The aggregates are determined turbidimetrically.

#### Reagents - working solutions

**R1** TRIS<sup>a)</sup> buffer with bovine serum albumin; preservatives

**R2** Latex particles coated with anti-CRP (mouse) in glycine buffer; immunoglobulins (mouse); preservative

a) TRIS = Tris(hydroxymethyl)-aminomethane

R1 is in position B and R2 is in position C.

#### Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: For prescription use only.

#### Reagent handling

Ready for use

Mix **cobas c** pack well before placing on the analyzer.

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

#### Storage and stability

##### CRPL3

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

##### Diluent NaCl 9 %

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

#### Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum.

Plasma: Li-heparin, K<sub>2</sub>-EDTA, K<sub>3</sub>-EDTA plasma

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

# CRPL3

## C-Reactive Protein Gen.3



Stability: <sup>11</sup>	11 days at 15-25 °C
	2 months at 2-8 °C
	3 years at (-15)-(-25) °C

### Materials provided

See "Reagents – working solutions" section for reagents.

### Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

### Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

### Application for serum and plasma

#### cobas c 311 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 8-18		
Wavelength (sub/main)	800/570 nm		
Reaction direction	Increase		
Units	mg/L (nmol/L, mg/dL)		
Reagent pipetting	Diluent (H <sub>2</sub> O)		
R1	150 µL		
R2	48 µL	24 µL	

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	2 µL	–	–
Decreased	4 µL	25 µL	75 µL
Increased	2 µL	–	–

#### cobas c 501 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 13-29		
Wavelength (sub/main)	800/570 nm		
Reaction direction	Increase		
Units	mg/L (nmol/L, mg/dL)		
Reagent pipetting	Diluent (H <sub>2</sub> O)		
R1	150 µL		
R2	48 µL	24 µL	

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	2 µL	–	–
Decreased	4 µL	25 µL	75 µL
Increased	2 µL	–	–

#### cobas c 502 test definition

Assay type	2-Point End
Reaction time / Assay points	10 / 13-29
Wavelength (sub/main)	800/570 nm
Reaction direction	Increase

Units	mg/L (nmol/L, mg/dL)	
Reagent pipetting	Diluent (H <sub>2</sub> O)	
R1	150 µL	
R2	48 µL	24 µL

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	2 µL	–	–
Decreased	4 µL	25 µL	75 µL
Increased	4 µL	–	–

### Calibration

Calibrators	S1: H <sub>2</sub> O
	S2: C.f.a.s. Proteins
	Multiply the lot-specific C.f.a.s. Proteins calibrator values by the factors below to determine the standard concentrations for the 6-point calibration curve:
	S2: 0.10000                      S5: 2.0000
	S3: 0.3325 (c 501/502)      S6: 4.0000
	0.3500 (c 311)
	S4: 1.0000
Calibration mode	6-point spline
Calibration frequency	Full calibration
	• after reagent lot change
	• as required following quality control procedures

Traceability: This method has been standardized against an internal method traceable to CRM 470 (RPPHS - Reference Preparation for Proteins in Human Serum).<sup>12</sup>

### Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

### Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	mg/L x 9.52 = nmol/L	mg/dL x 95.2 = nmol/L
	mg/L x 0.1 = mg/dL	mg/dL x 10 = mg/L
	mg/dL x 0.01 = g/L	g/L x 100 = mg/dL

### Limitations - interference

Criterion: Recovery within ± 10 % of initial values at a CRP concentration of 5.0 mg/L (47.6 nmol/L).

Icterus:<sup>13</sup> No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 60 mg/dL or 1026 µmol/L).

Hemolysis:<sup>13</sup> No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 622 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):<sup>13</sup> No significant interference up to an L index of 1000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors up to 1200 IU/mL do not interfere.

# CRPL3

## C-Reactive Protein Gen.3



High dose hook-effect: No false result occurs up to a CRP concentration of 1200 mg/L (11424 nmol/L).

Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>14,15</sup>

Therapeutic drugs: Significantly decreased CRP values may be obtained from samples taken from patients who have been treated with carboxypenicillins.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>16</sup>

Although measures were taken to minimize interference caused by human anti-mouse antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or have received them for diagnostic purposes.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

### ACTION REQUIRED

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCin1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

**Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.**

### Limits and ranges

#### Measuring range

0.3-350 mg/L (2.9-3333 nmol/L)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

#### Lower limits of measurement

##### Limit of blank and Limit of Detection

Limit of Blank = 0.2 mg/L (1.9 nmol/L)

Limit of Detection = 0.3 mg/L (2.9 nmol/L)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

##### Limit of Quantitation (Functional sensitivity)

0.6 mg/L (5.7 nmol/L).

The Limit of Quantitation was determined using the result of functional sensitivity testing. The Limit of Quantitation (functional sensitivity) is the lowest CRP concentration that can be reproducibly measured with an interassay coefficient of variation of < 20 %. It has been determined using low C-reactive protein samples.

### Expected values

Consensus reference interval for adults:<sup>17</sup> < 5 mg/L (< 47.6 nmol/L)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

### Precision

Precision was determined using human samples and controls in an internal protocol with repeatability ( $n = 21$ ) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Repeatability	Mean	SD	CV
	mg/L (nmol/L)	mg/L (nmol/L)	%
CRP T Control N	3.35 (32.4)	0.04 (0.4)	1.2
Precipath Protein	44.4 (422)	0.6 (5)	1.3
Human serum 1	0.57 (5.71)	0.02 (0.19)	3.6
Human serum 2	1.56 (15.2)	0.03 (0.3)	1.6
Human serum 3	43.2 (411)	0.5 (5)	1.2
Intermediate precision	Mean	SD	CV
	mg/L (nmol/L)	mg/L (nmol/L)	%
CRP T Control N	3.06 (29.1)	0.09 (0.9)	2.9
Precipath Protein	43.6 (415)	0.8 (8)	1.9
Human serum 1	0.51 (4.86)	0.06 (0.57)	11.1
Human serum 2	1.44 (13.7)	0.06 (0.6)	3.9
Human serum 3	41.3 (393)	0.7 (7)	1.7

### Method comparison

CRP values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared to those determined with the Tina-quant CRP (Latex) assay on a Roche/Hitachi 917 analyzer (x).

Sample size ( $n$ ) = 68

Passing/Bablok <sup>18</sup>	Linear regression
$y = 1.014x + 0.106$	$y = 1.008x + 0.422$
$r = 0.987$	$r = 0.999$

The sample concentrations were between 0.220 and 208 mg/L (2.09 and 1980 nmol/L).

CRP values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared to those determined with the CRPL2 reagent on a COBAS INTEGRA 800 analyzer (x).

Sample size ( $n$ ) = 69

Passing/Bablok <sup>18</sup>	Linear regression
$y = 0.941x + 0.166$	$y = 0.928x + 1.28$
$r = 0.983$	$r = 0.998$

The sample concentrations were between 0.525 and 221 mg/L (5.00 and 2104 nmol/L).

### References

- Greiling H, Gressner AM, eds. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3rd ed. Stuttgart/New York: Schattauer Verlag 1995:234-236.
- Thomas L. Labor und Diagnose, 7. Auflage, TH-Books Verlagsgesellschaft mbH, Frankfurt/Main 2008;1010-1021.
- Burtis CA, Ashwood ER, eds. Tietz Fundamentals of Clinical Chemistry, 5th ed. Pa: WB Saunders Co 2001;332-333.
- Thomas L, Messenger M. Pathobiochemie und Labordiagnostik der Entzündung. Lab med 1993;17:179-194.
- Young B, Gleeson M, Cripps AW. C-reactive protein: A critical review. Pathology 1991;23:118-124.
- Wasunna A, Whitelaw A, Gallimore R, et al. C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr 1990 Mar;149(6):424-427.
- Vergis N. Should CRP be used as a marker of infection in patients with liver cirrhosis? Clin Lab Int 2007;6:12-13.

# CRPL3

## C-Reactive Protein Gen.3




**cobas®**

- 8 Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. *Intensive Care Medicine* 2006;32:1344-1351.
- 9 Price CP, Trull AK, Berry D, et al. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. *J Immunol Methods* 1987;99:205-211.
- 10 Eda S, Kaufmann J, Roos W, et al. Development of a New Microparticle-Enhanced Turbidimetric Assay for C-reactive Protein with Superior Features in Analytical Sensitivity and Dynamic Range. *J Clin Lab Anal* 1998;12:137-144.
- 11 Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2. Jan. 2002.
- 12 Baudner S, Bienvenu J, Blirup-Jensen S, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins CRM470. Report EUR 15243 EN 1993;1-186.
- 13 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- 14 Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". *Eur J Clin Chem Clin Biochem* 1996;34:385-386.
- 15 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- 16 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.
- 17 Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). *Eur J Clin Chem Clin Biochem* 1996;34:517-520.
- 18 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

### Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

### FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, COBAS INTEGRA, PRECICONTROL, PRECINORM, PRECIPATH, and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

Distribution in USA by:  
Roche Diagnostics, Indianapolis, IN  
US Customer Technical Support 1-800-428-2336

